M ost companies hope to have a product where the demand for the item outstrips their ability to produce it, especially if the product can be protected by a patent. This is the potential case with Roche's oseltamivir (Tamiflu) . In past years, the demand for this product has been minimal compared to the current and potential future demand, especially if an influenza pandemic occurs.
Roche is an unenviable position in many ways. Roche has been faced with a business decision to increase the production of the product long before the real need for the product is realized and at the same time, balance the benefits to society and their financial responsibility to their stockholders. This does not simply mean making more units; it involves increasing capacity at manufacturing plants and possible construction of new facilities or outsourcing some of the production. If not enough drug is produced, there will be, and already has been, a public outcry of: "Why did they not produce more? They should have known better and predicted the need of this product." Along with this will be the issue of a sole-source product and pricing. Any price may be considered as price gouging by some. While if the production is increased, and the product remains unsold on pharmacy shelves, and in warehouses, their stockholders may hold them accountable for producing a poor return on their investment.
What is being done to help resolve this problem? Roche announced on November 7, 2005 the following points: • Their production network has been increased, so they will be able to produce 300 million treatments, annually, by the end of 2006 • The new capacity will be a tenfold increase over the capacity that was available in 2004 • They have received more than 150 requests from third parties (including other pharmaceutical manufacturers, generic manufacturers, and governments) regarding the production of oseltamivir • 3 million donated doses will be made available to the World Health Organization, if an influenza pandemic starts, with the hope that this might contain or stop the spread of the outbreak at its source There still remains the fact that Roche, and society, are at risk of unethical companies, or countries, deciding to ignore Roche's patents for Tamiflu and produce their own version of oseltamivir. Or worse, they could produce and distribute a counterfeit product.
In preparing for this potential pandemic, future outbreaks, or terrorist actions (eg, anthrax or other biological agents), we all should take a moment to remember that the public good should always take precedence over the needs of a single individual. Individual members, small groups, and companies should not be hoarding this medication. Instead, any stockpiles should be maintained by the government and its related health care agencies. Even the movie industry made this point in 1982 in a dialogue between Captain Kirk and Mr. Spock in Star Trek II: The Wrath of Kahn: Spock: Do not grieve, Admiral -it is logical: the needs of the many outweigh . . . Kirk: The needs of the few . . . Spock: Or the one.
We can only hope that society follows a community spirit of what is good the community is in the best interest of the individual, especially if this influenza pandemic does occur. ■
